These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 1659573)

  • 21. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells.
    Iwamoto J; Mizokami Y; Takahashi K; Matsuoka T; Matsuzaki Y
    Helicobacter; 2008 Jun; 13(3):174-82. PubMed ID: 18466392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
    Ploug M
    Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
    Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
    Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased invasion of neuroglioma cells transfected with urokinase plasminogen activator receptor cDNA.
    Mohanam S; Chintala SK; Mohan PM; Sawaya R; Lagos GK; Gokaslan ZL; Kouraklis GP; Rao JS
    Int J Oncol; 1998 Dec; 13(6):1285-90. PubMed ID: 9824646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
    Albo D; Berger DH; Rothman VL; Tuszynski GP
    J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
    Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
    Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the cellular binding site for the urokinase-type plasminogen activator.
    Estreicher A; Wohlwend A; Belin D; Schleuning WD; Vassalli JD
    J Biol Chem; 1989 Jan; 264(2):1180-9. PubMed ID: 2536017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration.
    McNeill H; Jensen PJ
    Cell Regul; 1990 Oct; 1(11):843-52. PubMed ID: 1965151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy.
    Yu W; Kim J; Ossowski L
    J Cell Biol; 1997 May; 137(3):767-77. PubMed ID: 9151680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
    Ploug M; Ellis V; Danø K
    Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE; Saunders DN; Ranson M
    Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
    Morrissey D; O'Connell J; Lynch D; O'Sullivan GC; Shanahan F; Collins JK
    Clin Exp Metastasis; 1999 Feb; 17(1):77-85. PubMed ID: 10390151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase.
    Ossowski L
    Cancer Res; 1992 Dec; 52(24):6754-60. PubMed ID: 1333882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.
    Roldan AL; Cubellis MV; Masucci MT; Behrendt N; Lund LR; Danø K; Appella E; Blasi F
    EMBO J; 1990 Feb; 9(2):467-74. PubMed ID: 1689240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subcellular distribution of urokinase and urokinase receptor in human neutrophils determined by immunoelectron microscopy.
    Pedersen TL; Plesner T; Horn T; Høyer-Hansen G; Sørensen S; Hansen NE
    Ultrastruct Pathol; 2000; 24(3):175-82. PubMed ID: 10914429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
    Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
    Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.